Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06087835 · ClinicalTrials.gov registry record · Phase 3
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
A Phase 3 study of Chronic Kidney Disease With High Proteinuria, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,835
- Enrollment target
- 20
- Study locations
NCT06087835: Active Phase 3 study of Chronic Kidney Disease With High Proteinuria, sponsored by AstraZeneca.
NCT06087835 is a Phase 3 study of Chronic Kidney Disease With High Proteinuria that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,835 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (138% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06087835, a Phase 3 study of Chronic Kidney Disease With High Proteinuria, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,835 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria
Primary Outcome
To determine whether zibotentan and dapagliflozin in fixed dose combination is superior to dapagliflozin alone to slow decline in kidney function
Conditions Studied
Interventions
- DRUG Dapagliflozin
- DRUG Zibotentan/Dapagliflozin
Study Locations (20)
California
- Research Site - Bakersfield
- Research Site - Huntington Park
- Research Site - Los Alamitos
- Research Site - Los Angeles
- Research Site - Northridge
- Research Site - Oxnard
- Research Site - San Carlos
- Research Site - San Dimas
- Research Site - Tarzana
- Research Site - Victorville
Florida
- Research Site - Boynton Beach
- Research Site - Hialeah
- Research Site - Hollywood
- Research Site - Jacksonville
- Research Site - Jensen Beach
- Research Site - Miami
Colorado
- Research Site - Arvada
- Research Site - Denver
Alabama
- Research Site - Huntsville
Arizona
- Research Site - Sun City West
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,835 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2027-01-22 |
| Phase | Phase 3 |
What the registry record for NCT06087835 still lists
NCT06087835 is an interventional study that assigns participants to a tested intervention. Its 1,835 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (138% higher).
The record links to 1 condition, with Chronic Kidney Disease With High Proteinuria appearing as the primary indexed condition, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT06087835 names 20 study sites across 5 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT06087835 about?
NCT06087835 is a clinical study titled "Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)". This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria
What is the current status of trial NCT06087835?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,835 participants. The study started on 2023-11-07. Estimated completion is 2027-01-22.
What conditions does trial NCT06087835 study?
This clinical trial studies the following conditions: Chronic Kidney Disease With High Proteinuria.
What interventions are being tested in trial NCT06087835?
The interventions under investigation include: Dapagliflozin (DRUG), Zibotentan/Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT06087835?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06087835 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06087835's enrollment target sits among peer trials
1,835 117th of 2000 higher than 1,884 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07104240 · 1,836 participants · NA
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
- NCT06740630 · 1,840 participants · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- NCT06465810 · 1,850 participants
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- NCT06580080 · 1,850 participants · NA
Evaluation of Are You Ready?
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI